Tissue engineering uses cells, signaling molecules, and/or biomaterials to regenerate injured or diseased tissues. Ex vivo expanded mesenchymal stem cells (MSC) have long been a cornerstone of regeneration therapies; however, drawbacks that include altered signaling responses and reduced homing capacity have prompted investigation of regeneration based on endogenous MSC recruitment. Recent successful proof-of-concept studies have further motivated endogenous MSC recruitment-based approaches. Stem cell migration is required for morphogenesis and organogenesis during development and for tissue maintenance and injury repair in adults. A biomimetic approach to in situ tissue regeneration by endogenous MSC requires the orchestration of three main stages: MSC recruitment, MSC differentiation, and neotissue maturation. The first stage must result in recruitment of a sufficient number of MSC, capable of effecting regeneration, to the injured or diseased tissue. One of the challenges for engineering endogenous MSC recruitment is the selection of effective chemoattractant(s). The objective of this review is to synthesize and evaluate evidence of recruitment efficacy by reported chemoattractants, including growth factors, chemokines, and other more recently appreciated MSC chemoattractants. The influence of MSC tissue sources, cell culture methods, and the in vitro and in vivo environments is discussed. This growing body of knowledge will serve as a basis for the rational design of regenerative therapies based on endogenous MSC recruitment. Successful endogenous MSC recruitment is the first step of successful tissue regeneration
Introduction
T he goal of tissue engineering is to orchestrate regeneration of injured or diseased tissue through the use of cells, signaling molecules, and/or biomaterials. [1] [2] [3] The rational design of regenerative therapies is guided by lessons learned from embryonic development, adult homeostasis, and stem cell biology. 1, [3] [4] [5] [6] [7] Stem cell migration is required for morphogenesis and organogenesis during development and for tissue maintenance and injury repair in adults. Recruitment of mesenchymal stem cells (MSC) to an injury site is the first stage of a biomimetic therapy for tissue regeneration.
MSC are a cornerstone of tissue engineering therapies because they have multilineage potential. MSC have been isolated from bone marrow 8 and many other tissues, including fat, periosteum, synovium, and dental pulp. [9] [10] [11] Evidence suggests that MSC reside in perivascular niches throughout the body. 12, 13 MSC differentiation has been demonstrated along mesodermal, 14 ectodermal, 15, 16 and endodermal 17 lineages. 11 MSC also support regeneration through trophic actions. 18, 19 Regenerative therapies have typically been based on ex vivo expanded bone marrow MSC (bMSC), delivered systemically 20, 21 or as part of a cell-scaffold construct. [22] [23] [24] However, there are drawbacks associated with MSC harvest and expansion, including cost, logistics, potential donor site morbidity, and regulatory hurdles. Ex vivo culture may also alter MSC signaling responses, 25 reduce homing capacity, [25] [26] [27] and alter immunogenicity. 28 Recruitment of endogenous MSC avoids these drawbacks, and there is growing recognition that in situ regeneration by endogenous MSC recruitment is a viable alternative or adjunctive to MSC transplantation. [29] [30] [31] [32] Approaches under development use chemoattactants to enhance migration of endogenous MSC to accelerate wound healing and/or colonize biomaterial scaffolds. [33] [34] [35] Recent proof of concept studies demonstrating tissue regeneration by endogenous MSC recruitment have motivated further development of this approach. [36] [37] [38] The most effective chemoattractants for recruiting endogenous MSC may vary with tissue type and remain to be determined.
MSC are recruited to locations in adult tissues by homing through the vascular network and by interstitial migration within tissue. 39 The mode of recruitment exploited in in situ tissue regeneration is chemotaxis, which is directional migration in response to a gradient of soluble chemoattractants, such as growth factors or chemokines. A key requirement for therapy success is the recruitment of a sufficient number of MSC to the injury site to achieve regeneration. 40 The focus of this review is chemoattractants for MSC recruitment. The mechanisms that govern MSC migration to injury sites have not been fully elucidated 27, 41 and are beyond the scope of this review. Biomaterials and strategies for chemoattractant delivery are described elsewhere. 31, 42 In recent years, a substantial body of work has been published in which various chemoattractants have been tested for MSC recruitment in vitro and in several in vivo models. The objective of this review is to synthesize and evaluate evidence of recruitment efficacy by reported MSC chemoattractants.
Growth Factors
Growth factors are polypeptide extracellular signaling molecules that stimulate cell survival, migration, proliferation, and differentiation. Growth factors play critical regulatory roles in embryogenesis 43 and in guiding wound repair. 44 bMSC express a variety of growth factor receptors (Table 1) .
PDGF-AA, PDGF-AB, PDGF-BB
Platelet-derived growth factor (PDGF) has important roles in the successive stages of embryogenesis and in wound healing. 45 PDGF is a polypeptide dimer with four homodimers, PDGF-AA, PDGF-BB, PDGF-CC, PDGF-DD, and one heterodimer, PDGF-AB. PDGF-CC and -DD are not discussed. PDGF has two receptor dimers, a and b. PDGF-AA binds a/a receptors, PDGF-AB binds a/a and a/b receptors, and PDGF-BB binds a/a, a/b, and b/b receptors. 46 In vitro, PDGF-AA, 47, 48 PDGF-BB, 47 and PDGF-AB 47, 49 were shown to be potent chemoattractants for human bMSC, with PDGF-BB generating the strongest response. 47 PDGF-AB also stimulated chemotaxis by ovine bMSC. 50 However, other studies reported only minimal recruitment of bMSC by PDGF-BB. 51, 52 The divergent conclusions may be due to MSC and/or culture condition differences. In a collagen gel invasion study, PDGF-BB induced minimal bMSC migration. 52 Migration was enhanced when bMSC were cocultured with PDGF-BB activated fibroblasts in a modified scratch assay. Blocking basic fibroblast growth factor (bFGF) and epithelial neutrophil activating peptide-78 produced by the fibroblasts inhibited the enhanced migration. The coculture study underscores the fact that migration may result from the integration of a number of chemotactic signals. In an in vivo tracking study in nude rats, PDGF-AA recruited nanoparticle-labeled human bMSC, which were injected into the proximal femoral medulary canal, to a fibrin scaffold in the distal femur, underscoring the promise of PDGF for regenerative therapies. 53 IGF-1, IGF-2, IGFBP-3, IGFBP-5
Insulin-like growth factors (IGF) are regulators of fetal and postnatal growth and development 54 and of bone growth, remodeling, and repair. 55 The IGF-1R receptor binds both IGF-1 and -2. 56 In vitro, IGF-1 and -2 stimulated migration by human bMSC in a dose-dependent manner. 57 IGF binding protein 5 (IGFBP-5) also induced migration. Adding IGFBP-5 to IGF-1 further enhanced IGF-1-stimulated migration; adding IGFBP-3 had no effect. Blocking the IGF-1R receptor inhibited migration completely. Other in vitro investigations have also reported IGF-1 to be a strong chemoattractant for human, 49, 58 rabbit, 58 and ovine 50 bMSC. Overexpression of IGF-1 in rat bMSC, resulted in enhanced recruitment to the infarcted heart and improved cardiac function in a rat model. 59 Overexpression also promoted expression of hepatocyte growth factor (HGF), bFGF, vascular endothelial growth factor (VEGF), and stromal cell derived factor-1 (SDF)-1a by bMSC and promoted cell survival in culture. IGF-1 also promotes cell proliferation, 60 making it a strong candidate for tissue regeneration therapies.
BMP-2, BMP-4, BMP-7, TGF-b1, TGF-b3
The bone morphogenetic proteins (BMP) and transforming growth factors -b (TGF-b) are members of the TGF-b superfamily of signaling molecules. The BMPs and TGF-bs are regulators of embryogenesis with essential roles in gastrulation, establishment of the dorsal-ventral axis, angiogenesis, and organogenesis, particularly skeletal formation. [61] [62] [63] [64] Postnatally, they play a prominent role in endochondral ossification, fracture healing, and bone remodeling. 61, 65 Receptors for the BMPs and TGF-bs are classified as type I and type II. 66, 67 Upon ligand binding, the receptors form a heterotetrameric complex composed of type I and type II receptor pairs. BMP-2, -4, and -7 are expressed during fracture healing. 65, 68, 69 In vitro, BMP-2, -4, and -7 stimulated chemotaxis BMP, bone morphogenetic protein; EGF, epidermal growth factor; HB-EGF, heparin-binding EGF; TGF, transforming growth factor; FGF, fibroblast growth factor; HGF, hepatocyte growth factor; IGF, insulin-like growth factor; PDGF, platelet-derived growth factor; VEGF, vascular endothelial growth factor.
by human bMSC, 48, 70 suggesting that their role in fracture healing may include bMSC recruitment. BMP-2 and -7 delivery have been studied extensively in animal models, and it has been approved as a clinical treatment for fracture nonunions and large segmental defects. 71, 72 TGF-b1 and -b3 are also expressed during fracture healing. 65 In vitro, TGF-b1 stimulated chemotaxis by human adipose-derived MSC (aMSC), 73 but not by bMSC. 70 TGF-b3 stimulated chemotaxis by human aMSC, synovium-derived MSC, and bMSC. 74 In vivo, sufficient cartilage was regenerated to cover the surface of a rabbit humeral head using only a scaffold infused with TGF-b3. 37 This cartilage regeneration was achieved by endogenous MSC recruitment. TGF-b superfamily members have considerable promise for bone and cartilage regeneration therapies.
EGF, HB-EGF, TGFa
Epidermal growth factor (EGF; EGFR) has pleiotropic effects that include migration, proliferation, differentiation, and dedifferentiation. 75 EGFR is expressed by epithelial and stromal cells and by some glial and smooth muscle cells. EGFR is either the sole or the overwhelmingly predominant receptor for several ligands, including EGF, heparin-binding EGF (HB-EGF), and TGF-a. In vitro, EGF stimulated chemotaxis by human, 58, 76 rat, 76 rabbit, 58 and ovine 50 bMSC. Human aMSC also migrated in response to EGF. 73, 77 HB-EGF stimulated chemotaxis by human and rabbit bMSC. 58 TGFa is structurally and functionally similar to EGF, sharing a 40% amino acid sequence identity. 78 TGF-a is upregulated in response to injury 79 and induces inflammation with ectopic expression. 80 It also induces production of VEGF by human bMSC. 81 In vitro, TGF-a stimulated chemotaxis by human bMSC. 58 A significant advantage of EGF is the stability of its native and recombinant forms, even under harsh conditions.
FGF-2
FGF-2, or bFGF, is a member of the FGF family that includes twenty-two structurally related proteins. 82, 83 FGF-2 plays a role in limb development, wound healing, and angiogenesis, 83, 84 and it contributes to cell survival, migration, proliferation, and differentiation. 82, 84, 85 Alternative splicing for FGF receptors (FGFR) 1-3 produces two isoforms, ''b'' and ''c.'' 82,86 FGF-2 preferentially activates the ''c'' isoforms (FGFR-1c, -2c, -3c) and has activity with FGFR-1b and FGFR-4. 86 The interaction of FGF with heparin and heparin sulfate plays an important role in FGF bioactivity. 82 Heparin binding protects FGF from proteolysis and thermal denaturation, limits the diffusion of FGF in the interstitial space, and results in a store of FGF that is released upon heparin cleavage. In vitro, FGF-2 stimulated chemotaxis by murine, 87 rabbit, 58 ovine, 50 and human 58, 88 bMSC and human aMSC. 73 FGF-2 stimulated chemotaxis for rat bMSC at passage two, but not at passage zero, 89 emphasizing that the effects of cell culture must be considered when interpreting results of in vitro chemotaxis assays.
HGF HGF (c-Met) is mitogenic and motogenic for hepatocytes and a variety of other cell types. 90 HGF plays a key role in organogenesis during embryonic development 91 and in wound healing. 92 In vitro, HGF stimulated chemotaxis by human 93, 94 and murine 95 bMSC. However, HGF administration also resulted in marked inhibition of bMSC proliferation. 93, 95 Exposure of murine bMSC to HGF resulted in the loss of markers associated with the MSC phenotype and expression of markers typical of early myogenic differentiation. 95 Additional research will be required to determine if this differentiation also occurs in vivo.
VEGF-A
The VEGF family has five members: VEGF-A through -D and placental growth factor. 96 Here, I focus on VEGF-A, which binds to the receptors VEGFR-1 and -2. 96, 97 VEGFs are essential for vasculogenesis and angiogenesis in the embryo and angiogenesis in the adult. VEGF-induced angiogenesis plays a key role in wound healing. 97 There is considerable variation in the results of in vitro studies that have evaluated VEGF-A as a chemoattractant for bMSC. The chemotactic response has been strong, 98, 99 weak, 88, 100 or absent. 58, 87 In a study, in which VEGF stimulated a strong chemotactic response, the human bMSC were found to be negative for VEGFR. 98 Based on receptor blocking studies, the authors concluded that the VEGF-A-induced migration was mediated by the structurally similar PDGF receptors. Additional research will be required to fully elucidate the intricacies of VEGF signaling in bMSC recruitment. Exposure of murine bMSC to hypoxia increased expression of VEGFR-1 and enhanced the chemotactic response to VEGF-A in vitro after hypoxia treatment. 99 Delivery of VEGF from a collagen gel in endodontically treated human teeth, that were implanted subcutaneously in a murine host, resulted in regeneration of deltal-pulp-like tissue. 101 These results demonstrate the potential of VEGF for tissue regeneration based on endogenous stem cell recruitment.
Chemokines
Chemotactic cytokines, or chemokines, are a family of small molecules of approximately 8-10 kDa in size that induce leukocyte migration. 102 They are classified into four groups based on the number and spacing of their cystein residues: CC, CXC, C, and CX 3 C. 103 Chemokines are key regulators of cell migration for tissue homeostasis, immune responses, and wound healing. bMSC express a variety of chemokine receptors (Table 2) .
SDF-1
SDF-1 (CXCL12; CXCR4) is expressed during embryonic development, 104, 105 at injury sites, 106, 107 and in response to hypoxia. [108] [109] [110] [111] There are two similar SDF-1 isoforms, SDF-1a and -1b. 112 In vitro, SDF-1b stimulated chemotaxis by human bMSC. 88, 113 In a rat hypoglossal nerve injury model, bMSC transplanted in the lateral ventricals migrated to injured tissue expressing SDF-1 and to the site of an intracerebral injection of SDF-1a. 114 In a murine bone fracture model, SDF-1 promoted bone regeneration by recruiting systemically delivered MSC to the fracture site. 107 Regeneration was inhibited by an anti-SDF-1 antibody and by a CXCR4 antagonist. In a murine model of myocardial infarction, systemically delivered bMSC migrated to infarcted
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tissue. 110 Elevation of SDF-1a expression by adenoviral gene delivery significantly increased MSC recruitment; a CXCR4 antagonist diminished recruitment. SDF-1a expression did not increase MSC recruitment in the absence of infarction. SDF-1 has also been exploited to recruit endogenous bMSC to, and to promote their migration within, biomaterial scaffolds. 115, 116 Collectively, these studies suggest that SDF-1 is an important chemokine for MSC recruitment.
MCP-1, MIP-1a, IL-8
Monocyte chemoattractant protein-1 (MCP-1, CCL2; CCR2), macrophage inflammatory protein-1a (MIP-1a, CCL3; CCR1,5), and interleukin-8 (IL-8, CXCL8; CXCR1,2) are expressed in rat ischemic cerebral tissue. 117, 118 Systemically infused bMSC migrated to ischemic cerebral tissue and reduced neurological functional deficits. 119 In vitro, extracts of ischemic brain tissue and recombinant MCP-1, 118 MIP1a, 113, 118 and IL-8 118 stimulated chemotaxis by human bMSC. MCP-1 is also transiently upregulated in the infracted heart. 120 In a murine model with MCP-1 specifically expressed in the heart, systemically infused murine bMSC engrafted in the hearts of transgentic mice, but not of wild-type controls. CCR2 antibodies inhibited MCP-1 induced migration. In an in vivo tracking study, nanoparticle-labeled human bMSC were injected into the proximal femoral medulary canal of nude rats. 53 MCP-1 or PDGF-AA was released from a heparin-conjugated fibrin scaffold in a distal femoral osteochondral defect. Both chemoattractants recruited bMSC to the scaffold; however, recruitment by MCP-1 was weak relative to that of PDGF-AA. These studies suggest that MCP-1, MIP-1a, and IL-8 may be valuable chemoattractants for regenerative therapies; however, growth factors may induce stronger responses.
RANTES, MDC
RANTES (regulated on activation normal T-cell expressed and secreted, CCL5; CCR1, 3, 4, 5) is a chemoattractant for Tcells, monocytes, and eosinophils. 121, 122 Macrophage-derived chemokine (MDC, CCL22; CCR4) is a chemoattractant for monocytes, monocyte-derived dendritic cells, and natural killer cells. 123 In vitro, both RANTES and MDC stimulated chemotaxis by human bMSC. 49 Preincubation of human bMSC with tumor necrosis factor a (TNF-a), an inflammatory cytokine, substantially increased the chemotactic response. CCR5 and its ligands are transiently upregulated in murine skin wounds. 124 Wound healing was delayed in CCR5 -/ -mice; however, systemic infusion of CCR5 + bone marrow-derived cells restored normal healing. MDC did not induce in vitro migration by human periostium-derived MSC. 125 These studies suggest that chemokine-induced migration may depend on the systemic and local inflammatory state and that MSC receptors may vary with tissue source.
Fractalkine
Fractalkine (CX 3 CL1; CX 3 CR1) mediates chemotaxis and adhesion of inflammatory cells, pain sensation, and is involved in several inflammatory conditions. [126] [127] [128] High levels of fractalkine and its receptor are expressed at wound sites. 114, 129 In vitro, fractalkine stimulated chemotaxis by MIP, macrophage inflammatory protein; RANTES, regulated on activation normal T-cell expressed and secreted; MCP, monocyte chemoattractant protein; TARC, thymus and activation-regulated chemokine; MDC, macrophage-derived chemokine; SLC, secondary lymphoid tissue chemokine; IL, interleukin; SDF, stromal cell derived factor. rat 114 and human 113, 130 bMSC; however, the potential of fractalkine for in vivo MSC recruitment has not been investigated.
SLC, TARC
Secondary lymphoid tissue chemokine (SLC, CCL21; CCR7) is a potent chemoattractant for lymphocytes and some T-cell lines. 131 Thymus and activation-regulated chemokine (TARC, CCL17; CCR4) is expressed by several cell types, including dendritic cells, endothelial cells, keratinocytes, and fibroblasts, and it is constitutively expressed in the thymus. 132 SLC 133 and TARC 132 are upregulated in several inflammatory skin conditions. In vitro, both SLC and TARC stimulated chemotaxis by murine bMSC. 15 In a murine skin wound model, local injections of SLC recruited systemically infused bMSC to the wound and accelerated healing; however, TARC injections had no effect. The difference between the in vitro and in vivo results for MSC recruitment underscores the complexity of MSC recruitment in the in vivo environment.
Other Chemoattractants
In addition to the better known growth factors and chemokines, other molecules have also been identified as MSC chemoattractants. Four examples of these other chemoattractants are reviewed. bMSC express receptors for these molecules (Table 3) .
LPA, S1P
Lysophospholipids, such as lysophosphatic acid (LPA) and sphingosine 1-phosphate (S1P), are bioactive signaling molecules that affect a variety of cell functions, including survival, migration, proliferation, and differentiation. 134, 135 LPA and S1P are released by activated platelets, and they may be as important as cytokines and growth factors in orchestrating tissue repair. 136 Thus far, there are five confirmed LPA receptors (LPA [1] [2] [3] [4] [5] ) and S1P receptors (S1P [1] [2] [3] [4] [5] ). 137 In vitro, LPA stimulated chemotaxis by human 138 and murine 87 bMSC. Human aMSC also migrated in response to LPA. 139 Migration was inhibited by Ki6425, an antagonist specific for LPA 1 and LPA 3 . In murine 140 and rat 141 cutaneous wound models, topical LPA application resulted in an accelerated healing response. S1P plays a key role in neovascularization for wound healing 142 and for cancer tumor growth. 143 Binding S1P 1 and S1P 2 had opposing effects on tumor angiogenesis in a murine study, with S1P 1 stimulating angiogenesis and S1P 2 inhibiting angiogenesis. 144 In vitro, S1P stimulated a chemotactic response by murine bMSC. 87, 145 The migration response for S1P was stronger than that for LPA. 87 In a murine model of liver fibrosis, S1P was elevated in the liver and serum after liver injury, and it stimulated migration of intravenously delivered bMSC to the liver. 146 Receptors S1P 1-3 were abundant on the bMSC recruited. Use of an S1P 3 antagonist markedly reduced bMSC migration both in vitro and in vivo.
146 Additional studies will be required to better understand the regulation of MSC by lysophospholipids and how these signaling molecules can be harnessed for tissue regeneration.
HMGB-1
High mobility group box-1 (HMGB-1) is a nonhistone DNA-binding cytokine that stabilizes nucleosomes and facilitates transcription.
147 HMGB-1 is passively released by injured and necrotic cells, but not by apoptotic cells, and it is secreted by activated macrophages and monocytes. 148 HMGB-1 in the extracellular compartment is recognized as a signal of tissue injury and a trigger to initiate tissue regeneration. However, HMGB-1 also contributes to pathological conditions, such as sepsis, rheumatoid arthritis, lupus, and cancer. HMGB-1 binds to the receptor for advanced glycation end products and toll-like receptors -2 and -4. 149, 150 In vitro, HMGB-1 stimulated transmigration by mesoangioblasts, a vessel-associated stem cell, through an endothelial barrier. 151 Beads containing HMGB-1 implanted in muscle resulted in recruitment of intravenously injected mesoangioblasts. HMGB-1 also stimulated migration by human bMSC in vitro. 149 Culture of bMSC with HMGB-1 suppressed proliferation in a dose-dependent manner and induced osteogenic differentiation. A better understanding of HMGB-1 signaling will be needed to harness its regenerative potential.
TNF-a
TNF-a is a proinflammatory cytokine produced by macrophages during acute inflammation of injured tissue. 152 TNF-a binds two receptors, TNFR-1 and -2, that are thought to activate distinct signaling pathways. 152 In vitro, TNF-a stimulated a strong dose-dependent migration response by rat bMSC 153 and by human aMSC 73 and bMSC. 49, 154 Preincubation of the aMSC with TNF-a enhanced the migration response to individual chemokines and growth factors. 73 However, preincubation of bMSC resulted in a stronger migration response to chemokines, but not to growth factors. 49 Incubation of human bMSC or aMSC with TNF-a stimulated production of VEGF, HGF, and IGF-1 by the MSC. 155 Neutralizing TNFR-2 significantly inhibited migration; neutralizing TNFR-1 had no affect on migration. 154 In a rat ischemia model, TNF, tumor necrosis factor; RAGE, receptor for advanced glycation end products; HMGB, high mobility group box; LPA, lysophosphatic acid; S1P, sphingosine 1-phosphate; TLR, Toll-like receptor.
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preincubation of rat bMSC with TNF-a before systemic infusion was associated with a greater bMSC accumulation in the ischemic muscle. 156 Additional research will be needed to determine if the migratory effects of TNF-a can be harnessed without introducing damaging inflammatory side-effects.
Ligands for toll-like receptors
Toll-like receptors (TLR) are a large family (TLR1-TLR11) of evolutionarily conserved receptors activated by intracellular components, such as heat shock proteins or RNA, that are released during wounding 157 and by invading pathogens. 158 These signals recruit immune cells to tissue injuries, 158 and it has recently been discovered that they may also recruit MSC. 159 In vitro, human bMSC migration was stimulated by ligands for TLR2-4 and TLR9. 157, 159 Preincubation with the ligands enhanced the migration response. However, in another study, TLR2 was reported to inhibit murine bMSC migration. 150 The discrepant results may be explained by the length of the preincubation period; a longer preincubation was shown to inhibit migration. 157 Interestingly, TLR signaling was also shown to regulate phenotype and differentiation down mesodermal pathways for human bMSC. TLR priming of a heterogenous bMSC population resulted in a nearly homogeneous phenotype.
157
TLR3-primed bMSC expressed primarily immunosuppressive mediators; TLR4-primed bMSC expressed primarily proinflammatory mediators. TLR3 ligand exposure inhibited osteogenic, adipogenic, and chondro-genic differentiation.
TLR4 ligand exposure stimulated osteogenic, inhibited adipogenic, and did not affect chondrogenic differentiation. TLR2 ligand exposure inhibited differentiation down each of the three pathways. 150 The TLRs are novel targets for inducing a more homogeneous response from heterogeneous MSC populations and for exerting an additional level of control over MSC differentiation.
Discussion
A biomimetic engineering approach to in situ tissue regeneration by endogenous MSC requires the orchestration of three main stages: MSC recruitment, MSC differentiation, and neotissue maturation. The first stage must result in the recruitment of a sufficient number of MSC that are capable of effecting regeneration of the injured or diseased tissue. One of the challenges for engineering endogenous MSC recruitment is the selection of effective chemoattractant(s).
Reported chemotactic responses vary among MSC isolated from the same tissue type and among MSC isolated from different tissue types. Differences in culture conditions and cell passage numbers contribute to the variation. Both cell density and passage number correspond to changes in MSC morphologies and gene expression levels of some phenotype markers. 25, 89, 160 Donor-related differences also contribute to the variance, 161 as do species-related, and even strain-related, differences. 89, 162 Differences among MSC isolated from different tissues 161, 163 may reflect the diversity among MSC niches. 164 Exposure of MSCs to a chemoattractant may stimulate collateral responses in addition to the chemotaxis desired. Treatment with TGFa, 81 TNF-a, 155 or overexpression of IGF-1 59 each stimulated the expression of other growth factors by the MSC. HGF inhibited proliferation and resulted in the loss of the MSC phenotype.
93,95 HMGB-1 inhibited proliferation and promoted osteogenic differentiation. 149 TLR priming changed MSC cytokine and chemokine expression patterns and differentiation responses; the changes were dependent on the TLR primed. 157 The in vitro and in vivo environments differ considerably; in vitro MSC chemotaxis may not translate to in vivo chemotaxis. In vitro, MSC are typically exposed to one chemoattractant, while in vivo, MSC are exposed to a multiplicity of signals that are influenced by the inflammatory state. In vivo, MSC are recruited from a tissue niche, while in vitro, MSC are recruited from a cell suspension or from a monolayer. In vivo, chemoattractants are subject to diffusion away from the regeneration site, enzymatic degradation, and/or deactivation. 31 In vivo, chemoattractants interact with the extracellular matrix. Proteoglycans bind, store, and release growth factors and chemokines. 165 Matrix binding has been shown to enhance growth factor function over that of the soluble form. 42 In vivo, other cells, such as fibroblasts, may also respond to a chemoattractant by migrating and/or by producing growth factors and chemokines. 58 Testing in animal models showed that lower doses of growth factor resulted in a greater chemotactic response 53 and that chemotaxis in vitro may not correspond to chemotaxis in vivo.
15
Much remains to be discovered about mechanisms that govern MSC chemotaxis; however, proof-of-concept studies have demonstrated the promise of endogenous MSC recruitment for tissue regeneration. Each chemoattractant reviewed has been reported to induce MSC chemotaxis. The key will be to determine which chemoattractant(s) (1) recruit a sufficient number of MSC capable of effecting regeneration, (2) do not recruit cells that interfere with regeneration, and (3) do not interfere with subsequent stages of tissue regeneration. The rational design of MSC recruitment strategies will require a synergistic combination of in vitro and in vivo experiments. Novel cell labeling techniques 53 will be required to monitor the spatiotemporal dynamics of MSC chemotaxis in vivo. Successful endogenous MSC recruitment is the first stage of successful tissue regeneration.
